Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

956
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
956
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

752
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
752
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

665
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
665
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

770
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
770
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.0K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.0K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

956
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
956

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute Aluminum Phosphide Poisoning: Evolving Perspectives on Toxic Mechanisms and Evidence-Based Clinical Management.

Xenobiotica; the fate of foreign compounds in biological systems·2026
Same author

Harnessing the immune system in lung cancer: emerging role of the microbiome.

Expert review of clinical immunology·2026
Same author

Manufacturing process development strategies for high concentration biologic drug products: from downstream processing to fill-finish.

Advanced drug delivery reviews·2026
Same author

Formation and degradation process of in situ forming implants - Attributes and impact on performance.

International journal of pharmaceutics·2026
Same author

Impact of ionizable lipid source on quality and stability of siRNA-loaded lipid nanoparticles.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Controlled Cisplatin Delivery Using pH-Sensitive PAA-Grafted Mesoporous Silica Nanoparticles.

ACS omega·2026

Related Experiment Video

Updated: Jan 27, 2026

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.7K

How can we develop better antispasmodics for irritable bowel syndrome?

Sheyda Ranjbar1, Seyed Afshin Seyednejad1, Shekoufeh Nikfar1,2

  • 1a Evidence-based Evaluation of Cost-Effectiveness and Clinical Outcomes , The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences , Tehran , Iran.

Expert Opinion on Drug Discovery
|March 29, 2019
PubMed
Summary

Developing new antispasmodics for irritable bowel syndrome (IBS) is crucial due to current treatment limitations. Rational drug design and a deeper understanding of IBS mechanisms are key to creating more effective and safer medications.

Keywords:
Irritable bowel syndromedrug discoverynew techniques

More Related Videos

Small Bowel Transplantation In Mice
36:30

Small Bowel Transplantation In Mice

Published on: August 20, 2007

15.1K
Eye Irritation Test EIT for Hazard Identification of Eye Irritating Chemicals using Reconstructed Human Cornea-like Epithelial RhCE Tissue Model
10:13

Eye Irritation Test EIT for Hazard Identification of Eye Irritating Chemicals using Reconstructed Human Cornea-like Epithelial RhCE Tissue Model

Published on: August 23, 2015

40.2K

Related Experiment Videos

Last Updated: Jan 27, 2026

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.7K
Small Bowel Transplantation In Mice
36:30

Small Bowel Transplantation In Mice

Published on: August 20, 2007

15.1K
Eye Irritation Test EIT for Hazard Identification of Eye Irritating Chemicals using Reconstructed Human Cornea-like Epithelial RhCE Tissue Model
10:13

Eye Irritation Test EIT for Hazard Identification of Eye Irritating Chemicals using Reconstructed Human Cornea-like Epithelial RhCE Tissue Model

Published on: August 23, 2015

40.2K

Area of Science:

  • Gastroenterology and Pharmacology
  • Drug Discovery and Development

Background:

  • Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by altered bowel habits and abdominal pain.
  • Current antispasmodics show variable efficacy, with some studies indicating no significant benefit over placebo.
  • There is a pressing need for the development of more effective and safer antispasmodic agents for IBS management.

Purpose of the Study:

  • To explore the role of rational drug design (RDD) in creating novel antispasmodics with improved characteristics.
  • To review potential pharmacological targets and herbal medicines exhibiting spasmolytic activity.
  • To present recent findings on novel mechanisms of gastrointestinal (GI) motility modulation and potential antispasmodic drugs from other therapeutic areas.

Main Methods:

  • Literature review focusing on rational drug design principles for antispasmodic development.
  • Exploration of pharmacological targets and herbal remedies for spasmolytic effects.
  • Analysis of recent research on GI motility regulation and repurposed drugs for antispasmodic potential.

Main Results:

  • Rational drug design (RDD) offers a strategic approach to developing antispasmodics with specific desired features.
  • Identification of potential pharmacological targets and natural products with spasmolytic properties.
  • Emerging insights into novel mechanisms regulating GI motility and the potential of existing drugs as antispasmodics.

Conclusions:

  • A deeper understanding of IBS-induced dysmotility and GI-specific receptors is essential for advancing antispasmodic development.
  • RDD, GI-restricted action, and multi-targeting strategies can lead to superior antispasmodics.
  • Formulation technologies and a multidisciplinary approach are vital for overcoming the complexity of IBS drug discovery.